Home › Compound Library › Tesamorelin (Egrifta)

Tesamorelin (Egrifta)

Peptideprescriptionsubcutaneous · inferred

Synthetic growth hormone-releasing hormone (GHRH) analog approved for treatment of HIV-associated lipodystrophy. Stimulates endogenous GH pulsatility. Very short half-life (26-38 min at steady state) with <4% bioavailability SC, but downstream IGF-1 elevation persists for 24 hours. Dosed daily.

Projected serum levels — 2 mg, once daily

Tesamorelin (Egrifta)
Tesamorelin (Egrifta) modeled serum levels, 2 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 2 mg once daily (subcutaneous).

Modeled steady state after ~1 days: peak ≈ 0.11 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a 2 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Peptide
Route modeled
Subcutaneous
Model confidence
inferred
Half-life
30 min
Common dose
2 mg
Suggested maximum
2 mg/day
Reference dose range
1–2 mg (single dose)
Suggested cadence
once daily
Validated against
2 mg sc — Cmax 0.003 mg/L at 0.25 h

Documented interactions

  • watch
    CJC-1295 DAC + Tesamorelin (Egrifta) Stacked effects

    CJC-1295 DAC and Tesamorelin (Egrifta) both push the ghrh receptor in the same direction.

  • watch
    CJC-1295 (no DAC) / Mod GRF 1-29 + Tesamorelin (Egrifta) Stacked effects

    CJC-1295 (no DAC) / Mod GRF 1-29 and Tesamorelin (Egrifta) both push the ghrh receptor in the same direction.

Serum checks 2 modeled interaction pairings for tesamorelin (egrifta) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Effects of a Growth Hormone-Releasing Hormone Analog on Endogenous GH Pulsatility and Insulin Sensitivity in Healthy Men Clemmons DR et al. · Journal of Clinical Endocrinology & Metabolism, 2011 DOI

    Demonstrated that once-daily tesamorelin augments basal and pulsatile GH secretion and significantly increases IGF-I while preserving peripheral insulin-stimulated glucose uptake.

  2. Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: pooled analysis of two phase 3 trials Falutz J et al. · Journal of Clinical Endocrinology & Metabolism, 2010 DOI

    Pooled analysis of two pivotal phase 3 RCTs showing tesamorelin significantly reduced visceral adipose tissue and improved lipid profiles in HIV-associated lipodystrophy.

  3. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV Falutz J et al. · New England Journal of Medicine, 2007 DOI

    Landmark NEJM trial demonstrating tesamorelin 2 mg daily significantly reduced trunk fat by 15.2% compared to placebo in HIV-infected patients with abdominal fat accumulation.

3 published studies referenced in the app, each with a plain-language summary.